Profile
Shaun Patrick Foy is the founder of CRISPR Therapeutics AG (founded in 2013), ERS Genomics Ltd.
(founded in 2014), and Xap Therapeutics Ltd (founded in 2017).
At CRISPR Therapeutics AG, he held the title of Director.
At ERS Genomics Ltd.
and Xap Therapeutics Ltd., he holds the title of Chairman.
Mr. Foy's current job is as an Advisor at Amplitude Ventures.
Mr. Foy's former job was as an Investment Adviser at Phase4 Partners Ltd.
from 2004 to 2008.
Mr. Foy received his undergraduate degree in 1993 and his graduate degree in 1997 from the University of British Columbia.
Shaun Foy active positions
| Companies | Position | Start |
|---|---|---|
ERS Genomics Ltd.
 ERS Genomics Ltd. BiotechnologyHealth Technology ERS Genomic Ltd. engages in the development of biotechnology. It was formed to provide broad access to the foundational CRISPR-Cas9, a new genome editing technology, which offers speed, efficiency, and cost over earlier genome editing methods. The company was founded by Emmanuelle Charpentier and Shaun Foy in 2014 and is headquartered in Dublin, Ireland. | Founder | 01/01/2014 |
Xap Therapeutics Ltd
 Xap Therapeutics Ltd Pharmaceuticals: MajorHealth Technology Xap Therapeutics Ltd is a British company that specializes in developing tailor-made therapies for the treatment of complex diseases such as cancer and autoimmunity. Xap Therapeutics is based in Cambridge, UK and was founded in 2017 by Shaun Patrick Foy and James Patterson. The company takes inspiration from the principle of exaptation and uses the power of genome editing and synthetic biology to convert nature's ultimate first-responder cell into a modular chassis, ready to be programmed to treat disease. The company's interdisciplinary team of exceptional scientists is key to its success. | Founder | 10/02/2017 |
Amplitude Ventures
 Amplitude Ventures Investment ManagersFinance Amplitude Ventures is a venture capital firm. The firm was founded in 2018. It’s headquartered in Montreal, Canada. | Consultant / Advisor | - |
Former positions of Shaun Foy
| Companies | Position | End |
|---|---|---|
Phase4 Partners Ltd.
 Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Private Equity Investor | 30/06/2008 |
| CRISPR THERAPEUTICS AG | Founder | - |
Training of Shaun Foy
| University of British Columbia | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CRISPR THERAPEUTICS AG | Health Technology |
| Private companies | 4 |
|---|---|
Phase4 Partners Ltd.
Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Finance |
ERS Genomics Ltd.
ERS Genomics Ltd. BiotechnologyHealth Technology ERS Genomic Ltd. engages in the development of biotechnology. It was formed to provide broad access to the foundational CRISPR-Cas9, a new genome editing technology, which offers speed, efficiency, and cost over earlier genome editing methods. The company was founded by Emmanuelle Charpentier and Shaun Foy in 2014 and is headquartered in Dublin, Ireland. | Health Technology |
Amplitude Ventures
Amplitude Ventures Investment ManagersFinance Amplitude Ventures is a venture capital firm. The firm was founded in 2018. It’s headquartered in Montreal, Canada. | Finance |
Xap Therapeutics Ltd
Xap Therapeutics Ltd Pharmaceuticals: MajorHealth Technology Xap Therapeutics Ltd is a British company that specializes in developing tailor-made therapies for the treatment of complex diseases such as cancer and autoimmunity. Xap Therapeutics is based in Cambridge, UK and was founded in 2017 by Shaun Patrick Foy and James Patterson. The company takes inspiration from the principle of exaptation and uses the power of genome editing and synthetic biology to convert nature's ultimate first-responder cell into a modular chassis, ready to be programmed to treat disease. The company's interdisciplinary team of exceptional scientists is key to its success. | Health Technology |
- Stock Market
- Insiders
- Shaun Foy
